CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-01-17 | Knapp Thomas J General Counsel | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2017-01-17 | Burns John Thomas Vice President, Finance | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2016-11-01 | Ghiglieri Stephen F Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,000,000 | 1,000,000 | ||
| 2016-10-25 | Knapp Thomas J General Counsel | Grant or award · Stock Option (right to buy) | +102,000 | 102,000 | ||
| 2016-07-14 | Nisi Rudolph Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | Hillsberg Sanford Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | Ashton William Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | GALLIKER STEPHEN S Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | GRAY MARY ANN Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | Einhorn Irving M. Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-14 | Chin Richard Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2016-07-01 | Nejadnik Bijan Chief Medical Officer | Other acquisition | +8,503 | $0.40 | $3K | 8,503 |
| 2016-07-01 | SCHWARTZ MARK W. President & CEO | Other acquisition | +8,503 | $0.40 | $3K | 439,978 |
| 2016-07-01 | Burns John Thomas Principal Accounting Officer | Other acquisition | +8,503 | $0.40 | $3K | 10,899 |
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise | +31,250 | $1.75 | $55K | 49,952 |
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise | +65,625 | $1.85 | $121K | 115,577 |
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise | +30,000 | $1.71 | $51K | 145,577 |
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Sale | −126,875 | $2.18 | $277K | 18,702 |
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise · Stock Option | −31,250 | 95,625 | ||
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise · Stock Option | −65,625 | 30,000 |
Page 11 of 17 · 324 trades